Navigation Links
Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
Date:3/27/2008

ALISO VIEJO, Calif., March 27 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it is scheduled to make an investor presentation at the B. Riley & Co. 9th Annual Las Vegas Investor Conference at 4:00 p.m. PDT (7:00 p.m. EDT) on Wednesday, April 2, 2008. The conference is being held at the Palms Casino Resort April 2-4, 2008.

A live webcast of the Company's presentation at the conference will be available via a link provided at http://www.clarientinc.com/investor . An archived replay of the presentation will be available shortly after the presentation time for a period of 90 days. Web participants are encouraged to go to the Company's website (http://www.clarientinc.com/investor ).

About Clarient

Clarient combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services
'/>"/>

SOURCE Clarient, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference
2. Clarient Named to Deloittes 2007 Orange County Technology Fast 50 for Third Consecutive Year
3. Clarient Generates 52% Revenue Increase in Third Quarter 2007
4. Clarient Names Michele Hibbard, Ph.D. Director of Genetics
5. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
6. Clarient to Present at the UBS 2007 Global Life Sciences Conference
7. Accurays CFO to Present at B. Riley & Company Ninth Annual Investor Conference
8. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
9. Bionovo to Present at the Cambria Capital Investor Meeting
10. UC Irvine researchers present latest findings at emergency medicine forum
11. BD to Present at the Leerink Swann Molecular Diagnostics Roundtable Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)...in harmless moles, may be key to diagnosis , ...lanoma produces high levels of a protein called IM..., University of Rochester Medical Center researche...ctors a new way to distinguish melanoma -- the mos...es that look like melanoma. , The study was pub...
(Date:7/23/2008)...wire-USNewswire/ -- The American Heart,Association...Lewis,Achievement Award, the association,s highest...rd was established in 2000, to recognize and honor...dical journalists who have documented,the consider...ase and,stroke. This career achievement award was ...
(Date:7/23/2008)...3 /PRNewswire-USNewswire/ -- The Alameda County,Pl...y 24-26 at the Oakland,Marriott to address the soc...n individuals from low-income and communities of c... and counties will attend. Place Matters,is a nati...and Economic,Studies, Health Policy Institute and ...
(Date:7/23/2008)... Dangerous for Morbidly Obese Women? ,As the o...re consulting plastic surgeons for breast reductio...d been thought to have higher complication rates. ... as safe to perform large-volume breast reductions...tudy title: Breast Reduction: Safe in the Morbidly...
Breaking Medicine News(10 mins):Health News:Protein Gives Doctors New Tool to Detect Melanoma 2Health News:Alameda County Hosts National Initiative to Reduce Health Disparities 2
...od testing in children of Mt Isa today to determin...over emissions from Xstrata's two Mount Isa smelte...on Agency raised concerns about the need for healt... Blood sample will be collected from 400 children ...
... genes, REG1A and EXTL3 in the patients with color...ding to a new study from the Max Delbrueck Center ...ssion was also significantly higher in surgical bi...us colon polyps, or adenomas. "The findings sugg...
... output of nerve cells is the messenger of informa...ll unclear about how widely separated regions of t...r to assist a complex activity. A new study by neu...keley, and neurosurgeons and neurologists at UC Sa...
...nes is needed to make them more user-friendly and ...he latest edition of the Medical Journal of Austra... care has become a major feature of health care, y...recommendations are frequently not applied in prac...
Other Medicine News:Health News:REG1A and its receptor EXTL3 signal the recurrence of colorectal cancer 2Health News:Slow brain waves integral in coordination of complex activity 2Health News:Getting More Out of Guidelines 2
(Date:7/21/2008)...on use of Zevalin as consolidation therapy after ...ts with follicular ... -- Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA:...led,a meeting with the U.S. Food and Drug Administ...ty of filing a supplemental Biologics License,Appl...
(Date:7/21/2008)...wire/ -- The SEAS (Simvastatin and Ezetimibe in,Ao...of intensive,cholesterol lowering with the combina...0 mg daily) in patients with aortic stenosis., Ao...the aortic valve in,the heart) is a relatively com...ons. Left untreated, it can progress to death from...
(Date:7/21/2008)...is a Must for Clinical Trials Management, WASHING...ation of,Academic Health Centers (AAHC) today laun...designed to assist academic health center leaders,...icers in establishing,strengthening, and improvin...ch enterprise, particularly to manage and support ...
(Date:7/21/2008)...ewswire/ -- Bioimpedance spectroscopy (BIS) is,mor...linical assessment of,lymphedema in breast cancer ...ly 20 issue of Journal of Clinical Oncology (2008;...ema After Breast Cancer: Incidence, Risk Factors, ...hored by Sandra Hayes, PhD.,and colleagues from Q...
Breaking Medicine Technology:CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 2CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 3CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 4Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 2Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 4New AAHC Toolkit Available to Optimize Clinical Research Administration 2Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology 2Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology 3Sales of Etimicin Sulfate to Expand Nationwide as Government Restriction is Lifted 1168 1Sales of Etimicin Sulfate to Expand Nationwide as Government Restriction is Lifted 1168 2Thermo Fisher Scientific Acquires Leader in Micro Volume Spectrophotometers NanoDrop Technologies 1166 1Thermo Fisher Scientific Acquires Leader in Micro Volume Spectrophotometers NanoDrop Technologies 1166 2Thermo Fisher Scientific Acquires Leader in Micro Volume Spectrophotometers NanoDrop Technologies 1166 3SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT 40776 for the Treatment of Overactive Bladder 1164 1SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT 40776 for the Treatment of Overactive Bladder 1164 2Surgeons Develop Innovative Life Saving Treatments to Correct Massive Bleeding in Trauma Patients 477 1Surgeons Develop Innovative Life Saving Treatments to Correct Massive Bleeding in Trauma Patients 477 2Surgeons Develop Innovative Life Saving Treatments to Correct Massive Bleeding in Trauma Patients 477 3Surgeons Develop Innovative Life Saving Treatments to Correct Massive Bleeding in Trauma Patients 477 4Surgeons Develop Innovative Life Saving Treatments to Correct Massive Bleeding in Trauma Patients 477 5
... 05, 2007 /PRNewswire-FirstCall/ --,Nuvelo, Inc. t...linical study of novel monoclonal antibodies again...trate that NTB-A is a,potential new target for imm...ia and lymphomas. The study, entitled "The lymphoi...antibody target for,leukemia and lymphoma therapeu...
...SS WIRE)--Jun 5, 2007 - NovaDel Pharma,Inc. (AMEX:...ng,oral spray formulations for a broad range of ma...inical studies comparing zolpidem,oral spray with ...netic (PK), pharmacodynamic (PD) and safety object...mbien(R), a leading,drug for the treatment of inso...
Other Medicine Technology:Nuvelo Announces Publication of Preclinical Study Results,Demonstrating the Potential of NTB-A as a New Target for Leukemia,and Lymphomas 2Nuvelo Announces Publication of Preclinical Study Results,Demonstrating the Potential of NTB-A as a New Target for Leukemia,and Lymphomas 3Nuvelo Announces Publication of Preclinical Study Results,Demonstrating the Potential of NTB-A as a New Target for Leukemia,and Lymphomas 4NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 2NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 3NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 4NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 5NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 6NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 7
...nstruments are designed to provide distraction of ...ate preparation, and insertion of interbody grafts... Intradiscal Wedges, Spanners, Nerve Root Retracto...(Anterior Thoracic Interbody Fusions), TLIF, PLIF,...
...let Concentrate System is a point-of-care system d...entrate (also referred to as Platelet Rich Plasma ... sample of blood. The Symphony II PCS concentrates...d in the platelets. The platelet concentrate can b...
...et gel has an extensive base of experience and kno... concentrated autologous platelets are mixed with ...tional changes involved in coagulation take place....rs including serotonin, fibronectin, adenosine dip...
The Leica 2D video system offers you two smart solutions for microsurgical video imaging. The Leica 2D pick-up system, an integrated camera module to fit on all Leica M-series and the Leica 2D C-moun
Medicine Products: